Taylor Eddens1,2, Brian T Campfield1,3, Katelin Serody1, Michelle L Manni4, William Horne1, Waleed Elsegeiny1,2, Kevin J McHugh4, Derek Pociask5, Kong Chen1, Mingquan Zheng1, John F Alcorn4, Sally Wenzel6, Jay K Kolls1. 1. 1 Richard King Mellon Foundation Institute for Pediatric Research and. 2. 2 Department of Immunology. 3. 3 Division of Pediatric Infectious Diseases, Department of Pediatrics, and. 4. 4 Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania. 5. 5 Department of Pulmonary Diseases, Critical Care, and Environmental Medicine, Tulane University School of Medicine, New Orleans, Louisiana. 6. 6 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and.
Abstract
RATIONALE: Infection with Pneumocystis, an opportunistic fungal pathogen, can result in fulminant pneumonia in the clinical setting of patients with immunosuppression. In murine models, Pneumocystis has previously been shown to induce a CD4+ T cell-dependent eosinophilic response in the lung capable of providing protection. OBJECTIVES: We sought to explore the role of Pneumocystis in generating asthma-like lung pathology, given the natural eosinophilic response to infection. METHODS: Pneumocystis infection or antigen treatment was used to induce asthma-like pathology in wild-type mice. The roles of CD4+ T cells and eosinophils were examined using antibody depletion and knockout mice, respectively. The presence of anti-Pneumocystis antibodies in human serum samples was detected by ELISA and Western blotting. MEASUREMENTS AND MAIN RESULTS: Pneumocystis infection generates a strong type II response in the lung that requires CD4+ T cells. Pneumocystis infection was capable of priming a Th2 response similar to that of a commonly studied airway allergen, the house dust mite. Pneumocystis antigen treatment was also capable of inducing allergic inflammation in the lung, resulting in anti-Pneumocystis IgE production, goblet cell hyperplasia, and increased airway resistance. In the human population, patients with severe asthma had increased levels of anti-Pneumocystis IgG and IgE compared with healthy control subjects. Patients with severe asthma with elevated anti-Pneumocystis IgG levels had worsened symptom scores and lung parameters such as decreased forced expiratory volume and increased residual volume compared with patients with severe asthma who had low anti-Pneumocystis IgG. CONCLUSIONS: The present study demonstrates for the first time, to our knowledge, that Pneumocystis is an airway allergen capable of inducing asthma-like lung pathology.
RATIONALE: Infection with Pneumocystis, an opportunistic fungal pathogen, can result in fulminant pneumonia in the clinical setting of patients with immunosuppression. In murine models, Pneumocystis has previously been shown to induce a CD4+ T cell-dependent eosinophilic response in the lung capable of providing protection. OBJECTIVES: We sought to explore the role of Pneumocystis in generating asthma-like lung pathology, given the natural eosinophilic response to infection. METHODS:Pneumocystis infection or antigen treatment was used to induce asthma-like pathology in wild-type mice. The roles of CD4+ T cells and eosinophils were examined using antibody depletion and knockout mice, respectively. The presence of anti-Pneumocystis antibodies in human serum samples was detected by ELISA and Western blotting. MEASUREMENTS AND MAIN RESULTS:Pneumocystis infection generates a strong type II response in the lung that requires CD4+ T cells. Pneumocystis infection was capable of priming a Th2 response similar to that of a commonly studied airway allergen, the house dust mite. Pneumocystis antigen treatment was also capable of inducing allergic inflammation in the lung, resulting in anti-Pneumocystis IgE production, goblet cell hyperplasia, and increased airway resistance. In the human population, patients with severe asthma had increased levels of anti-Pneumocystis IgG and IgE compared with healthy control subjects. Patients with severe asthma with elevated anti-Pneumocystis IgG levels had worsened symptom scores and lung parameters such as decreased forced expiratory volume and increased residual volume compared with patients with severe asthma who had low anti-Pneumocystis IgG. CONCLUSIONS: The present study demonstrates for the first time, to our knowledge, that Pneumocystis is an airway allergen capable of inducing asthma-like lung pathology.
Entities:
Keywords:
Pneumocystis; T cells; allergic inflammation; asthma
Authors: Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls Journal: J Clin Invest Date: 2005-11-23 Impact factor: 14.808
Authors: M Bradley Drummond; Laurence Huang; Philip T Diaz; Gregory D Kirk; Eric C Kleerup; Alison Morris; William Rom; Michael D Weiden; Enxu Zhao; Bruce Thompson; Kristina Crothers Journal: AIDS Date: 2015-08-24 Impact factor: 4.177
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Michael R Edwards; Nathan W Bartlett; Tracy Hussell; Peter Openshaw; Sebastian L Johnston Journal: Nat Rev Microbiol Date: 2012-06-06 Impact factor: 60.633
Authors: Maryam Salimi; Jillian L Barlow; Sean P Saunders; Luzheng Xue; Danuta Gutowska-Owsiak; Xinwen Wang; Li-Chieh Huang; David Johnson; Seth T Scanlon; Andrew N J McKenzie; Padraic G Fallon; Graham S Ogg Journal: J Exp Med Date: 2013-12-09 Impact factor: 14.307
Authors: Megan N Januska; David L Goldman; Wilmore Webley; W Gerald Teague; Robyn T Cohen; Supinda Bunyavanich; Alfin G Vicencio Journal: Pediatr Pulmonol Date: 2019-11-15
Authors: Taylor Eddens; Waleed Elsegeiny; Maria de la Luz Garcia-Hernadez; Patricia Castillo; Giraldina Trevejo-Nunez; Katelin Serody; Brian T Campfield; Shabaana A Khader; Kong Chen; Javier Rangel-Moreno; Jay K Kolls Journal: Cell Rep Date: 2017-03-28 Impact factor: 9.423
Authors: Taylor Eddens; Rachel Wolfe; Andrew Nowalk; Erick Forno; Brian T Campfield Journal: Ann Allergy Asthma Immunol Date: 2021-01-17 Impact factor: 6.347
Authors: S L Vargas; C Ponce; R Bustamante; E Calderón; G Nevez; Y De Armas; O Matos; R F Miller; M J Gallo Journal: Eur J Clin Microbiol Infect Dis Date: 2017-06-05 Impact factor: 3.267
Authors: Diego A Rojas; Pablo A Iturra; Andrea Méndez; Carolina A Ponce; Rebeca Bustamante; Miriam Gallo; Pamela Bórquez; Sergio L Vargas Journal: Sci Rep Date: 2019-02-14 Impact factor: 4.379
Authors: Taylor Eddens; Waleed Elsegeiny; David Ricks; Meagan Goodwin; William T Horne; Mingquan Zheng; Jay K Kolls Journal: mSphere Date: 2019-09-04 Impact factor: 4.389